HARNESSING CRISPR-CAS9 GENE EDITING FOR TARGETED THERAPY IN SOLID TUMORS: CHALLENGES AND FUTURE DIRECTIONS

Abstract

The possibilities of using advanced gene editing technologies, specifically CRISPR-Cas9, for developing therapies in oncology are truly remarkable. Solid tumors, which are immensely complex and highly diverse genically, are often some of the most difficult tumors to treat, making them ideal candidates for precise targeted therapies. This review looks into the existing studies related to the research of CRISPR-Cas9 for solid tumors, analyzing the key technological bottlenecks in the field, such as delivery systems, off-target effects, and immune evasion. Furthermore, we discuss recent progress toward achieving these goals and overcoming ethical and regulatory barriers and suggest areas for further investigation and practice. Ultimately, we wish to determine the levels of CRISPR-Cas9 gene editing and immunotherapy that can be deployed for solid tumors, anticipating the dawn of a new generation in precision oncology. It has been concluded that incorporation of CRISPR-Cas9 in the treatment of solid tumors is a dynamic, evolving arena of research that promises revolutionizing oncology through more precise and personalized therapies. The obstacles are enormous—technological, ethical and regulator ones. Yet, continued advances in CRISPR technology and deepening understanding of tumor biology can open possibilities for highly effective novel cancer treatments that are, both in safety and efficacy, superior to existing modalities in the future.